<< Medical tourism industry affected by economic recession, may grow by 35% by 2010, says report | Axolotl launches Elysium Image Exchange >>

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

26. October 2009 08:57

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

The company will hold a conference call on Tuesday, October 27^th at 11 a.m. eastern time to discuss the data presented at the conference. Interested parties may access the call by dialing (877) 407-0778 domestically, or (201) 689-8565 internationally. A replay of the call will be available until November 10, 2009, and can be accessed by dialing (877) 660-6853 domestically, or (201)-612-7415 for international audiences, and using account # 286 and Conference ID #: 336119.

The call will also be available via a simultaneous live webcast, and can be accessed by visiting http://iq-vcall.incommsolutions.com and using InComm IQueue Conference Number: 00336119. Please note that webcast audiences must use Internet Explorer to access the broadcast.

Source: ImmunoCellular Therapeutics, Ltd.

0d4a1e55-93f4-4946-9b36-63dd742cf697|0|.0

Posted in: Drug Trial News | Pharmaceutical News

Tags: Antibody, Biotechnology, Brain, Brain Tumor, Cancer, Cell, Dendritic Cell, Education, Glioblastoma, Immunization, Lung Cancer, Monoclonal Antibody, Multiple Myeloma, Neurosurgery, Ovarian Cancer, Pancreatic Cancer, Vaccine

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitorMillennium: The Takeda Oncology Company today announced it has further expanded its protein homeosta...Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-BrainNorthwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period fro...Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patientsBiogen Idec and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies’ lon...Guide reveals that non-smokers require different treatment for lung cancerA committee of scientists led by Johns Hopkins investigators has published a new guide to the biolog...Banner Good Samaritan treats cancers and neurological disorders with the Novalis Tx radiosurgery platformJohn J. Kresl, M.D., Ph.D., and colleagues at Banner Good Samaritan Medical Center are now treating ...Research journal to host a webinar on apoptotic signalling in normal and cancer cell biologyThe business office of Science, the world's leading peer-reviewed research journal, is producing a w...Metformin associated with reduced risk of pancreatic cancer in diabeticsThe antidiabetic medication metformin is associated with a reduced risk of pancreatic cancer in diab...New drug blocks common cancer pathwayScientists have developed a new drug which can reduce the growth of tumours in mice by up to 98 per ...New insights into how to combat avian fluAn in-depth analysis of blood from patients recovering from the H5N1 avian influenza virus has provi...Xencor and CSL Limited establish antibody optimization collaborationXencor, Inc., an antibody discovery and development company, announced today that it has entered int...Mumps making a comeback in AustraliaExperts are concerned that mumps, once a thing of the past, may be making a comeback in Australia an...Children's Brain Tumor Foundation's tissue bank consortium may solve dire problem in pediatric cancer researchIn a major effort to speed treatment and cures for pediatric brain tumors and cancer, the Children's...Low childhood IQ linked to dementia risk later in lifeThe researchers from Edinburgh University compared the records of 173 people who took part in the Sc...CDC says one in four children are out of compliance with U.S. vaccination guidelinesYour toddler might be improperly vaccinated, even if she's had every immunization the government rec...Safer treatment for depressionResearchers from the University of Pittsburgh, with the help of a team of Pittsburgh high school sci...TCF21 gene shown to be a tumor suppressorResearchers have identified a new and unusual tumor suppressor gene that may be important in cancers...Promising new cancer drug, NanotaxA Lawrence company that uses patented technology created at the University of Kansas to improve the ...

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Add comment

Quirky Comment Title
Name*
E-mail* (Will show your Gravatar icon)
Country Country flag

b i u quote

Comment
Preview

Notify me when new comments are added

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

Recent Articles

Free!

Recent Comments

Twitter

Information

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

Medical News Cloud

Recent Articles